Combination of medullary thyroid cancer and renal cell carcinoma in one patient
Yuliya A. Dolinskaya,
Sergey P. Shevchenko,
Vladimir N. Maksimov,
Elena N. Voropaeva,
Oksana D. Rymar 
Abstract
Patients who received treatment for the first malignant neoplasm remain in the group at increased risk of developing a second primary tumor throughout their later life. A rare case of medullary thyroid cancer and renal cell carcinoma of the kidney is described in one patient. Medullary thyroid cancer is an orphan disease. The patient and his first-line relatives underwent molecular-genetic testing, the presence of a hereditary form of medullary cancer was excluded. During the observation, malignant kidney formation was detected, and surgical treatment was performed. The patient because of treatment and surveillance does not have data for the progression of thyroid cancer and kidney cancer, compensation for concomitant diseases has been achieved. When observing patients with medullary thyroid cancer, it is necessary to use the existing modern diagnostic arsenal, including positron emission tomography, since patients remain in the group at increased risk of disease progression and development of the second tumor throughout the entire subsequent life. In addition, this case clearly illustrates the need for a routine study of calcitonin as a diagnostic marker for the progression of medullary thyroid cancer.
About the Authors
Yuliya A. DolinskayaInstitution of Internal and Preventive Medicine
Russian Federation
Sergey P. Shevchenko
Novosibirsk State University
Russian Federation
MD, PhD, professor
Vladimir N. Maksimov
Institution of Internal and Preventive Medicine
Russian Federation
MD, PhD, professor
Elena N. Voropaeva
Institution of Internal and Preventive Medicine
Russian Federation
PhD
Oksana D. Rymar
Institution of Internal and Preventive Medicine
Russian Federation
MD, PhD
References
1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83(12):2638-2648. doi: 10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31> 3.0.co;2-1.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Thyroid Carcinoma. Version 1.2009. National Comprehensive Cancer Network, Inc.; 2009.
3. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658-5671. doi: 10.1210/jcem.86.12.8070.
4. Shaha AR, Cohen T, Ghossein R, Tuttle RM. Late-onset medullary carcinoma of the thyroid: need for genetic testing and prophylactic thyroidectomy in adult family members. Laryngoscope. 2006;116(9): 1704-1707. doi: 10.1097/01.mlg.0000233509.83679.ee.
5. Sipple JH. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med. 1961;31(1):163-166. doi: 10.1016/0002-9343(61)90234-0.
6. Steiner AL, Goodman AD, Powers SR. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing’s disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore). 1968;47(5):371-409.
7. Bensalah K., Ljungberg B., Bex A., и др. Рекомендации Европейской ассоциации урологов 2014 г. Почечно-клеточный рак. // РМЖ. – 2014. – Т. 22. – №17. – С. 1218–1233. [Bensalah K, Ljungberg B, Bex A, et al. EAU guidelines on renal cell carcinoma: 2014 update. RMZh.2014;22(17):1218-1233. (In Russ.)]
8. Lal G, Groff M, Howe JR, et al. Risk of subsequent primary thyroid cancer after another malignancy: latency trends in a population-based study. Ann Surg Oncol. 2012;19(6):1887-1896. doi: 10.1245/s10434-011-2193-2.
9. Abdel-Rahman O. Risk of subsequent primary kidney cancer after another malignancy: a population-based study. Clin Genitourin Cancer. 2017;15(5):e747-e754. doi: 10.1016/j.clgc.2017.02.004.
10. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565-612. doi: 10.1089/thy.2008.0403.
11. Абдулхабирова Ф.М., Бельцевич Д.Г., Ванушко В.Е., и др. Диагностика и лечение медуллярного рака щитовидной железы. // Эндокринная хирургия. – 2012. – Т. 6. – №1. – C. 5–17. [Abdulkhabirova FM, Bel’tsevich DG, Vanushko VE, et al. Medullary Thyroid Cancer: Management Guidelines. Endocrine surgery. 2012;6(1):5-17. (In Russ.)] doi: 10.14341/2306-3513-2012-1-5-17.
12. Долинская Ю.А., Шевченко С.П., Воропаева Е.Н. Молекулярная диагностика медуллярного рака щитовидной железы в Новосибирске. / Сборник тезисов VII Всероссийского конгресса эндокринологов; Москва, 2–5 марта 2016 г. – М.; 2016. – С. 78. [Dolinskaya YA, Shevchenko SP, Voropaeva EN. Molekulyarnaya diagnostika medullyarnogo raka shchitovidnoy zhelezy v Novosibirske. In: Proceedimgs of the 7th All-Russian Congress of Endocrinologists; Moscow, 2–5 Mar 2016. Moscow; 2016. p. 78. (In Russ.)]
Supplementary files
|
|
1. Fig. The level of calcitonin (pg / ml) during the observation period (reference values for men 0-8.4 pg / ml). | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(99KB)
|
Indexing metadata ▾ | |
Review
For citations:
Dolinskaya Yu.A., Shevchenko S.P., Maksimov V.N., Voropaeva E.N., Rymar O.D. Combination of medullary thyroid cancer and renal cell carcinoma in one patient. Clinical and experimental thyroidology. 2018;14(1):34-38. (In Russ.)
Views:
2430
Email this article 
